REDWOOD CITY, Calif., Nov. 10 Cardica, Inc.(Nasdaq: CRDC) today announced publication of a case study in the Septemberissue of the peer-reviewed Journal of Neurosurgery featuring the use ofCardica's C-Port xA(R) Distal Anastomosis System to connect blood vessels inthe brain to bypass an enlarging aneurysm.
Ralph G. Dacey, Jr., M.D., professor and chairman of neurological surgeryat Washington University School of Medicine in St. Louis, and his colleaguesperformed neurosurgery on a 43-year-old male patient who sustained asubarachnoid hemorrhage after being assaulted and, as a result, experienced anenlarging aneurysm. Using the C-Port system, the neurosurgeons bypassed theaneurysm using a saphenous vein graft extending from the extracranial commoncarotid artery to the intracranial middle cerebral artery. The C-Port systemperformed an automated anastomosis by inserting 13 tiny staples into the graftand recipient vessel. The bypass was demonstrated to be patent (open) onintraoperative and postoperative arteriography, and the patient subsequentlymade a good neurologic recovery.
"By using the C-Port system instead of hand sewing the vessels in thebrain, we were able to reliably connect the graft vessel and significantlyreduce the length of time that blood flow was cut off from the brain in thispatient," said Dr. Dacey. "In appropriate patients, we believe the C-Portsystem is a useful addition to the arsenal of tools that neurovascularsurgeons have to surgically bypass cerebral aneurysms. We are looking forwardto using it in other suitable cases."
The Journal of Neurosurgery September issue also included results from apreclinical feasibility study of the use of the C-Port xA system to connectblood vessels in neurological bypass procedures. The study, conducted bysurgeons at the University of Bern, Washington University and Heinrich-Heine-Universitat in Dusseldorf, demonstrated that the C-Port xA could reliably andconsistently perform an anastomosis for an extracranial-intracranial high-flowbypass to the middle cerebral artery.
"Publication of the first use of the C-Port xA system in a successfularterial bypass in a patient with an intracranial aneurysm, together with theresults of the neurologic preclinical feasibility study, demonstrate theversatility and diverse functionality of Cardica's C-Port systems inconnecting blood vessels," said Bernard A. Hausen, M.D., Ph.D., president andchief executive officer of Cardica. "We are exploring additional applicationsfor our automated anastomosis systems in cerebrovascular neurosurgery andother fields beyond cardiothoracic surgery."
Cardica is a leading provider of automated anastomosis systems forcoronary artery bypass graft (CABG) surgery. By replacing hand-sewn sutureswith easy-to-use automated systems, Cardica's products provide cardiovascularsurgeons with rapid, reliable and consistently reproducible anastomoses, orconnections of blood vessels, often considered the most critical aspect of theCABG procedure. Cardica's C-Port(R) Distal Anastomosis Systems are marketed inthe United States and Europe and its PAS-Port(R) Proximal Anastomosis Systemis marketed in the United States, Europe and Japan. Cardica also is developingadditional devices with Cook Medical to facilitate vascular closure and othersurgical procedures.
This press release contains "forward-looking" statements, includingstatements relating to the potential expansion of uses for and increasedadoption of the C-Port systems, specifically, and of automated anastomosisdevices generally, for CABG and neurological procedures. Any statementscontained in this press release that are not historical facts may be deemed tobe forward-looking statements. The words "exploring," "looking," "believe" orsimilar expressions are intended to identify forward-looking statements. Thereare a number of important factors that could cause Cardica's results to differmaterially from those indicated by these forward-looking statements, includingrisks associated with the need for Cardica's products to gain marketacceptance, and the long-term patency rates of grafts connected usingCardica's products, as well as other risks detailed from time to time inCardica's SEC reports, including its Annual Report on Form 10-Q for the fiscalyear ended September 30, 2008. Cardica does not undertake any obligation toupdate forward-looking statements. You are encouraged to read the Cardica'sreports filed with the U.S. Securities and Exchange Commission, available athttp://www.sec.gov.
SOURCE Cardica, Inc.